Blinded vs Unblinded Clinical Trial Data Explained

Blinding is one of the most important concepts in clinical trials. A blinded trial is designed so that patients, investigators, the company or some combination of these do not know which treatment each patient received.

What is blinded data?

Blinded data means the treatment assignments are hidden. In a blinded oncology trial, the company may know total number of patients, total number of events, pooled safety data, pooled survival follow-up and enrollment progress, but not which events happened in each arm.

What is unblinded data?

Unblinded data reveal the results by treatment arm: experimental arm mOS, control arm mOS, hazard ratio, p-value, adverse events by arm and response rate by arm.

What is pooled data?

Pooled data combine both arms. A company may say “fewer than 50% of all enrolled patients have died.” That does not tell investors whether the experimental drug is working.

Why pooled survival can mislead investors

The same pooled event count can imply very different outcomes. In a 100-patient trial with 45 deaths, the split could be 20/25, 25/20, 10/35 or 35/10. Only arm-level data can reveal treatment effect.

Blinded event delays

In event-driven trials, delayed events can sound bullish. But if the trial is blinded, delayed events may be caused by strong experimental performance, strong control performance, both arms performing well, slow enrollment, patient selection, improved standard of care or long survival tails.

Read more: What Is an Event-Driven Clinical Trial?

Investor checklist

Ask whether the trial is still blinded, whether the update is pooled or arm-level, what event count has been reached, what event count triggers final analysis, whether median follow-up was reported, whether the control arm could be outperforming and what will be revealed at unblinding.

Bottom line

Pooled blinded data can suggest something is happening, but only unblinded arm-level data can show whether the drug works.